Rgenta Therapeutics Announces Strategic Alliance with GSK to …
Dec 4, 2024 · Rgenta to receive a cash upfront and pre-option milestone payments. Rgenta has the potential to receive milestone payments, royalties, and a future equity investment
Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC …
Oct 23, 2024 · New preclinical data on PRMT5-MTA inhibitor program will also be presented. NEW YORK, NY, USA I October 23, 2024 I Schrödinger (Nasdaq: SDGR) today announced new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, during a poster session at the 36th EORTC-NCI-AACR Symposium (ENA 2024). The data demonstrate that in preclinical models, treatment with SGR-3515 results in ...
ESSENCE Phase 3 trial results demonstrating statistically significant ...
Nov 20, 2024 · The trial achieved both its primary endpoints, with semaglutide 2.4 mg demonstrating statistically significant and superior improvements in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis in people with MASH compared to placebo. 1 Supportive secondary endpoints showed improvements in liver enzymes, including ...
QRL-101 is the only Kv7 ion channel opener being actively studied …
Dec 4, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Merck’s Investigational Zilovertamab Vedotin in Combination With …
Dec 9, 2024 · Based on data, 1.75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate. RAHWAY, NJ, USA I December 08, 2024 I Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of data from the Phase 2 waveLINE-007 trial evaluating zilovertamab vedotin, Merck’s investigational antibody drug ...
Shaperon Enrolls Its First Patient in Phase 2 U.S. Clinical Trial for ...
Mar 18, 2024 · 210 Patients With Multi-Racial Atopic Dermatitis…Phase 2 Clinical Trial Begins. CAMBRIDGE, MA, USA & SEOUL, South Korea I March 18, 2024 I Shaperon, Inc. (Kosdaq: 378800), a biotechnology company developing innovative immune drugs, announced the enrollment of the first patient in the Phase 2 clinical trial …
First single-dose medicine for P. vivax malaria prequalified by …
Dec 4, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Pfizer’s IBRANCE® in Combination with Standard-of-Care …
Dec 14, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) …
Dec 8, 2024 · Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease control, as measured by lactate dehydrogenase (LDH) levels, compared to standard-of-care ravulizumab
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint ...
Dec 20, 2024 · Primary statistical analysis of overall survival compared TA-TMA patients treated with narsoplimab in its pivotal trial to a cohort of over 100 TA-TMA patients not treated with narsoplimab in an external control stem cell transplant registry; FDA-agreed analysis was conducted by an independent external statistical group